By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ipsen 

39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609


SEARCH JOBS


Industry
Pharmaceutical






Company News
Ipsen (IPN.PA) Reports 12.2%1 Sales Growth For The Third Quarter Of 2016 And Raises Full Year Guidance 10/26/2016 10:06:31 AM
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Announce Positive Results From Phase 2 CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma Presented At The European Society For Medical Oncology (ESMO) 2016 Congress 10/10/2016 11:55:27 AM
Exelixis (EXEL) And Ipsen (IPN.PA) To Host Investor And Media Briefing To Discuss Data Presented At The ESMO 2016 Congress 10/4/2016 11:11:20 AM
Ipsen (IPN.PA) Announces Nine Poster Presentations At The 2016 North American Neuroendocrine Tumor Society (NANETS) Symposium 9/30/2016 10:52:39 AM
Ipsen (IPN.PA) Announces Data Presentations Of Cabozantinib (Cabometyx), Lanreotide (Somatuline® Autogel®) And Telotristat Ethyl* At The European Society For Medical Oncology (ESMO) 2016 Congress 9/27/2016 10:57:15 AM
Ipsen (IPN.PA) Announces Data Presentation for Dysport (abobotulinumtoxinA) At American Academy Of Cerebral Palsy And Developmental Medicine 9/22/2016 8:07:10 AM
Ipsen (IPN.PA) Announces Eight Presentations For Dysport (Abobotulinumtoxina) At The Annual Meeting Of The American Association Of Neuromuscular & Electrodiagnostic Medicine 9/16/2016 7:43:06 AM
European Commission (EC) Approves Ipsen (IPN.PA)’s Cabometyx (Cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma (RCC) In Adults Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy 9/14/2016 10:22:59 AM
Ipsen (IPN.PA) Announces FDA Approval Of Dysport (Abobotulinumtoxina) For Injection For The Treatment Of Lower Limb Spasticity In Children Aged Two And Older 8/1/2016 11:26:05 AM
Ipsen (IPN.PA) Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Pediatric Patients Aged Two And Older 8/1/2016 9:43:44 AM
12345678910...
//-->